Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

ESTRADIOL HEMIHYDRATE & PROGESTERONE

All products: general benefit

Bijuva · DIN 02505223 · 1mg & 100mg · capsule

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Bijuva · DIN 02505223 Manufacturer: Knight Therapeutics Inc.; listing date 2024-02-29 Health Canada: Marketed since 2024-01-31 · brand BIJUVA · ATC G03FA04 PROGESTERONE AND ESTROGEN · form Capsule · route Oral · ingredients ESTRADIOL (ESTRADIOL HEMIHYDRATE) 1 MG, PROGESTERONE 100 MG · company Knight therapeutics inc. · schedule Prescription
Check this DIN again · Health Canada product record

Bijuva: Formulary list price $0.9143/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.9143 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99458 · Verify on the e-Formulary ↗ (DIN 02505223)

Source record
DIN 02505223: Bijuva Raw flags: sec3=Y Item: 681600082; group id 736; item number 1804; lccId None; manufacturer id KNT Source form: Cap; strength: 1mg & 100mg Recorded listing: General benefit Source prices (unrounded): $0.9143; ministry $0.9143 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02505223 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99458
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (68:16 Estrogens) and how they are covered

Matched class: 68:16 Estrogens

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ESTRADIOL 17-B, ESTRADIOL HEMIHYDRATE Some products covered without a code (check the product listing): CONJUGATED ESTROGENS, ESTRADIOL 68:16 Estrogens

CONJUGATED ESTROGENS

· 2 products · Limited Use, codes 398 (1), General benefit (1) · strengths: 0.625mg, 0.625mg/g · SR Tab, Vag Cr

ESTRADIOL

· 7 products · Listed, not a benefit (3), General benefit (4) · strengths: 0.5mg, 1mg, 2mg · Tab, Vag Ring

ESTRADIOL 17-B

· 1 products · General benefit · strengths: 10mcg · Vag Tab with Applicator

ESTRADIOL HEMIHYDRATE

· 2 products · General benefit · strengths: 4mcg, 10mcg · Vag Insert Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:16
Full class listing Related classes: 68:04 Corticosteroids, 68:08 Androgens, 68:12 Contraceptives, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:32 Progestogens and Oral Contraceptives, 68:36 Thyroids, 68:38 Anti-Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS BIJUVA (estradiol and progesterone capsule) is indicated for: • Treatment of moderate to severe vasomotor symptoms associated with menopause in women with an intact uterus. BIJUVA is recommended for use only in patients with an intact uterus since the regimen includes a progestogen whose role is to assist in the prevention of endometrial hyperplasia. 1.1 Pediatrics Pediatrics (<18 years of age): BIJUVA is not indicated for pediatric use. 1.2 Geriatrics Geriatrics (>65 years of age): BIJUVA has not been studied in women over 65 years old; therefore, BIJUVA is not recommended in women over 65 years of age. https://pdf.hres.ca/dpd_pm/00077597.PDF PM date: SEP 16, 2020 Source product: BIJUVA; DIN 02505223; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.